Why Immediate-Release ADHD Boosters Can Undermine Adherence
Immediate-release ADHD booster doses can be hard for patients with executive dysfunction to manage because they must recall when doses are due, work out timing, and decide whether to take them. A panel explains how this burden can weaken treatment adherence.
For people with ADHD, executive dysfunction can make planning, memory, and follow-through difficult. When treatment includes immediate-release booster doses, patients must recall when another dose is due, work out timing, and decide whether to take it. Those repeated decisions add cognitive burden. The panel explains that this burden can weaken treatment adherence. The issue sits within broader mental health care, where the practical demands of a treatment plan can affect whether patients follow it.
This story may affect patients with ADHD, their caregivers, and clinicians. If immediate-release boosters require repeated recall and timing decisions, some patients could find consistent adherence harder, potentially affecting treatment outcomes. The greatest impact may fall on those with executive dysfunction, who already face organizational demands. Clinicians and families may need to consider how dosing routines fit daily life, though experiences will vary.